A


2.00
1.80
1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
Absorbance
anti-IgG
anti-IgM
anti-IgA
Specificity of secondary antibody

B


2.00
1.80
1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
Absorbance
anti-IgG
anti-IgM
anti-IgA
Specificity of secondary antibody

Figure 1


Top wick
A
B
Nitrocellulose strip
Sample application site
Substrate-coated gelbond
Luminescence measuring window
Bottom wick
C
D
Chase injection port
Conjugate hinge in closed position
lever

Figure 2

A


500000
450000
400000
350000
300000
250000
200000
150000
100000
50000
0
RLUs
117
11.7
5.9
1.17
0.12
0
µg/ml anti-HCV Antibody

B


0 0.12 1.17 5.9 11.7 117
µg/ml anti-HCV antibody

Figure 3



Figure 4



Figure 5


Sample #
1
2
3
4
5
6
7
8
9
NS4 (3)
NS4 (2)
NS4 (1)
Core (2)
Core (1)
E2
Mean HCV(-)
+ 2 SD
STRONG
weak
Relative immunoreactivity to peptide antigens

Figure 6



1. Top wick
2. Sample combined with labeled detection molecule
3. Trapping zone with immobilized peptide antigens
4. Bottom wick
5. Patient IgA, IgM, IgE and Ig G antibodies labeled with detection molecule bound to peptides of trapping zone



Avidin

Biotinylated HCV peptides

Direction of sample flow

Figure 7